Detalhe da pesquisa
1.
Biology and therapeutic targeting of molecular mechanisms in MPNs.
Blood
; 141(16): 1922-1933, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534936
2.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
3.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
4.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Blood
; 141(15): 1817-1830, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706355
5.
Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow.
Mod Pathol
; 37(1): 100352, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839675
6.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
7.
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies.
Acta Haematol
; 147(2): 198-218, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673048
8.
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax.
Cancer
; 129(22): 3535-3545, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584267
9.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
10.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
11.
Defining disease modification in myelofibrosis in the era of targeted therapy.
Cancer
; 128(13): 2420-2432, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499819
12.
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Blood
; 141(15): 1884-1888, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332187
13.
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Am J Hematol
; 95(3): 245-250, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804723
14.
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.
Mod Pathol
; 32(9): 1373-1385, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31000771
15.
PhALLCON Soars to New Heights-Faster, Stronger, but Better?
JAMA
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722663
16.
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.
Am J Hematol
; 93(11): 1358-1367, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30117174
17.
Regulation of ribosomal gene expression in cancer.
J Cell Physiol
; 230(6): 1181-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25336383
18.
Advancements and Challenges in the Treatment of AML.
Am Soc Clin Oncol Educ Book
; 44(3): e438662, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662975
19.
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Front Immunol
; 15: 1359113, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38571944
20.
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
Leukemia
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538860